First-line Rucaparib Plus Bevacizumab Maintenance Completed One-Year in Germline BRCA1-Mutated Advanced Ovarian Cancer

The present case study showed the novel approach of Rucaparib and Bevacizumab as first-line maintenance therapy in germline BRCA 1 mutated advanced high-grade serous carcinoma of the ovary. A 56-year-old female with high-grade serous carcinoma of the ovary (ECOG PS1) was treated with carboplatin and...

Descripción completa

Detalles Bibliográficos
Autores principales: Roy, Somnath, Ghosh, Joydeep, Ganguly, Sandip, Biswas, Bivas, Bhaumik, Jaydip
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Obstetrics/Gynecology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837332/
https://www.ncbi.nlm.nih.gov/pubmed/36644062
http://dx.doi.org/10.7759/cureus.32493

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837332/
https://www.ncbi.nlm.nih.gov/pubmed/36644062
http://dx.doi.org/10.7759/cureus.32493

Ejemplares similares